NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
Clinical Trials
55 trialsNCT06625775 2026-03-18
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT06917079 2026-03-18
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT07221357 2026-03-17
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06179160 2026-03-16
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
Phase 1 Recruiting
NCT07284849 2026-03-16
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT06663319 2026-03-13
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07221149 2026-03-04
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT04929223 2026-03-03
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT04068610 2026-03-02
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
Phase 1/2 Active not recruiting
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT05855200 2026-01-23
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline
Phase 3 Recruiting
NCT07265674 2026-01-23
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3 Recruiting
NCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT05836324 2025-12-18
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT06936527 2025-09-03
XS-03-II201
NovaOnco Therapeutics Co., Ltd.
Phase 1/2 Enrolling by invitation
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05864105 2025-03-12
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Biotheus Inc.
Phase 2 Active not recruiting
NCT06225843 2025-02-19
EGIA-003
Alethia Biotherapeutics
Phase 2 Recruiting
NCT03662659 2025-02-05
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
Phase 2 Completed
NCT03526835 2025-01-29
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
Phase 1/2 Recruiting
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT05039944 2024-07-18
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT00851136 2022-12-13
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Genentech, Inc.
Phase 1 Completed
NCT00364013 2022-11-07
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Amgen
Phase 3 Completed
NCT04991948 2022-03-09
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Celyad Oncology SA
Phase 1 Recruiting
NCT02923921 2020-10-19
Sequoia
Eli Lilly and Company
Phase 3 Completed
NCT03035253 2020-08-11
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
Mereo BioPharma
Phase 1 Terminated
NCT00724503 2019-03-26
SIRFLOX
Sirtex Medical
Phase NA Completed
NCT01632306 2019-01-15
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Terminated
NCT02069041 2018-11-21
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00551213 2018-08-24
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT03362684 2017-12-05
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
IntegraGen SA
Phase 3 Completed
NCT01418222 2017-05-30
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT00384176 2017-04-14
HORIZON III
AstraZeneca
Phase 2/3 Completed
NCT00399035 2016-12-28
HORIZON II
AstraZeneca
Phase 3 Completed
NCT00873756 2016-11-02
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT02215837 2016-05-24
Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT02202928 2015-12-28
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT00440310 2015-08-25
Phase 3 Trial of Litxâ„¢ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Light Sciences Oncology
Phase 3 Completed
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00890305 2015-07-08
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Medivation, Inc.
Phase 2 Completed
NCT00778830 2015-05-14
APEC
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT00494221 2014-03-27
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
Phase 1/2 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed